Published in Int J Cancer on July 03, 1998
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood (2010) 1.03
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther (2005) 0.83
Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment. BMC Cancer (2003) 0.77
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A (1993) 4.97
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science (1992) 3.05
CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol (2004) 2.71
CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res (1991) 2.36
Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med (1993) 2.03
Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol (1992) 1.89
CD44 splice variants: metastases meet lymphocytes. Immunol Today (1993) 1.50
Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer (2001) 1.34
Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med (2000) 1.31
The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res (1993) 1.28
A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res (1993) 1.26
Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res (1989) 1.18
Characterization of BSp73, a spontaneous rat tumor and its in vivo selected variants showing different metastasizing capacities. Invasion Metastasis (1983) 1.17
Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy. J Cell Biol (1998) 1.13
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol (1999) 1.11
Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer (1990) 1.11
Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci (2001) 1.10
Requirement for CD44 in proliferation and homing of hematopoietic precursor cells. J Leukoc Biol (1996) 1.10
Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol (2006) 1.10
Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene (2012) 1.09
CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol (2000) 1.09
Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene (1998) 1.07
Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol (1998) 1.05
Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol (1996) 1.03
Cell configuration and adhesive properties of metastasizing and non-metastasizing BSp73 rat adenocarcinoma cells. Exp Cell Res (1986) 0.99
CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab Invest (1999) 0.99
Differential expression of intermediate filament proteins in metastatic and nonmetastatic variants of the BSp73 tumor. Cancer Res (1986) 0.93
Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer (1992) 0.92
Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Arch (2001) 0.91
Bronchoconstriction in nonhuman primates: a species comparison. J Appl Physiol (1985) (2011) 0.91
In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol (2000) 0.91
Developmentally regulated expression of metastasis-associated antigens in the rat. Cell Growth Differ (1996) 0.90
Sensitization of leukocytes of cancer patients against fetal antigens: leukocyte migration studies. J Natl Cancer Inst (1979) 0.89
Inhibition of cell-mediated cytotoxicity to chemically induced rat tumours by soluble tumour and embryo cell extracts. Int J Cancer (1976) 0.89
Upregulation of C4.4A expression during progression of melanoma. J Invest Dermatol (2001) 0.88
Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol (2000) 0.87
Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch Gynecol Obstet (1996) 0.87
The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and exert non-overlapping functional activities. Int Immunol (2000) 0.86
Alopecia areata in a rhesus monkey (Macaca mulatta). J Med Primatol (2007) 0.86
C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br J Cancer (2007) 0.86
Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells. J Immunol (1996) 0.85
Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis. Adv Exp Med Biol (1998) 0.85
Leukocyte migration studies in gastric cancer detection: an approach toward improved specificity and sensitivity. J Natl Cancer Inst (1977) 0.85
T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1. Immunobiology (2001) 0.85
Metastasis-association of the rat ortholog of the human epithelial glycoprotein antigen EGP314. Oncogene (1999) 0.84
Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene (2001) 0.84
Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch (1996) 0.83
Natural killer cells do not belong to the recirculating lymphocyte population. Scand J Immunol (1982) 0.83
Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin Cancer Res (2001) 0.82
CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopathol (1998) 0.82
Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res (1995) 0.82
Rat macrophages inhibit natural killer (NK) cell activity against adherent growing target cells. Immunobiology (1982) 0.82
Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. J Cell Sci (1997) 0.82
Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells. Exp Hematol (2001) 0.82
Iodination of immunoadsorbed antibodies: chloramine T vs lactoperoxidase. Immunochemistry (1977) 0.82
Normally occurring inhibitory cells for natural killer cell activity. I. Organ distribution. Cell Immunol (1982) 0.82
Characterization of natural cytotoxicity in vitro in a spontaneous rat tumor model. J Immunol (1980) 0.82
Cytotoxic T lymphocyte responses to spontaneous tumors: immunogenicity dependent on the recognition of processed tumor antigens. J Immunol (1983) 0.82
Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation. Drugs Exp Clin Res (2003) 0.82
Identification of renal-cell-carcinoma-related cDNA clones by suppression subtractive hybridization. J Cancer Res Clin Oncol (1999) 0.81
Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression. Leuk Res (1996) 0.81
Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity. Immunol Lett (1997) 0.81
Expression of CD44 variant isoforms in malignant melanoma. Clin Cancer Res (1996) 0.81
No evidence for cancer-related CD44 splice variants in primary and metastatic colorectal cancer. Eur J Cancer (1998) 0.81
High incidence of spontaneous transplantable tumours in BDX rats. Br J Cancer (1978) 0.81
Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother Pharmacol (2001) 0.81
Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther (2001) 0.81
Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol (1999) 0.80
Cell-mediated cytotoxicity to chemically-induced rat tumours. Int J Cancer (1975) 0.80
Blockade of metastasis formation by CD44-receptor globulin. Int J Cancer (1998) 0.80
Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress. J Invest Dermatol (1999) 0.80
Normally occurring inhibitory cells for natural killer cell activity. II. Characterization of the inhibitory cell. Cell Immunol (1982) 0.79
CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol (1997) 0.79
Proceedings: Cell mediated immune reactions against rat tumour cells detected by in vitro microcytotoxicity assays. Br J Cancer (1975) 0.79
Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments. Int J Cancer (1999) 0.78
Evaluation of 51Cr release for detecting cell-mediated cytotoxic responses to solid chemically induced rat tumours. Br J Cancer (1977) 0.78
Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes. J Invest Dermatol (1998) 0.78
Down-modulation of host reactivity by anti-CD44 in skin transplantation. Transplantation (1998) 0.78
In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system. Cancer Gene Ther (1999) 0.78
Functional activity of CD44 isoforms in haemopoiesis of the rat. Br J Haematol (1997) 0.78
Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene (1996) 0.78
Oscillation of antibody production and regulatory T cells in response to antigenic stimulation. Eur J Immunol (1985) 0.78
Cytotoxic T-cell precursors against non-immunogenic rat tumors: limiting dilution analysis. Int J Cancer (1986) 0.78
Autoreactive antibodies in thymus and spleen of neonatal and young adult BALB/c mice: influence of prenatal tolerization. Scand J Immunol (1991) 0.78
Expression of CD44 isoforms carrying metastasis-associated sequences in newborn and adult rats. Eur J Cancer (1993) 0.78
Limiting dilution analysis of the frequencies of helper and suppressor T cells in untreated and TNP-treated BALB/c mice: response as a consequence of perturbation of a stable steady state. Immunology (1985) 0.78
Time course analysis of regulation of cytotoxic T cells. Cell Immunol (1985) 0.78
Expression of CD44 splice variants in normal, dysplastic, and neoplastic cervical epithelium. Clin Cancer Res (1995) 0.78
Analysis of molecular functions of the tumor metastasis promoting surface molecule CD44v4-v7 using transgenic mice. Princess Takamatsu Symp (1994) 0.78
A modified leucocyte migration assay as indicator of malignant and non-malignant gastric mucosal alteration. Digestion (1977) 0.77
Involvement of CD44 exon v10 in B-cell activation. Tissue Antigens (1998) 0.77
Comparison between the in vitro activities of in vivo-induced hapten-specific suppressor cells and supernatants of a hapten-specific suppressor hybridoma. Cell Immunol (1984) 0.77
Tumour-induced suppression of immune response and its correction. Cancer Immunol Immunother (2001) 0.77
Importance of CD44v7 isoforms for homing and seeding of hematopoietic progenitor cells. J Leukoc Biol (2001) 0.76
Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo. Clin Cancer Res (2001) 0.76
Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther (2000) 0.76
Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro. Eur J Immunol (2001) 0.76